Table 4.
Transplantation-related concomitant morbidities diagnosed among transplantation patients during the 12-month follow-up period
| Allo-HSCT | Renal SOT | Non-renal SOT | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| All patients n = 226 |
CMV n = 66 |
No CMV n = 160 |
p value | All patients n = 128 |
CMV n = 20 |
No CMV n = 108 |
p value | All patients n = 122 |
CMV n = 22 |
No CMV n = 100 |
p value | |
| Renal impairmenta | 115 (50.9) | 44 (66.7) | 71 (44.4) | 0.003 | – | – | – | – | 93 (76.2) | 18 (81.8) | 75 (75.0) | 0.593 |
| BM depressionb | – | – | – | – | 24 (18.8) | 7 (35.0) | 17 (15.7) | 0.060 | 63 (51.6) | 13 (59.1) | 50 (50.0) | 0.487 |
| Neutropenia | – | – | – | – | 13 (10.2) | 5 (25.0) | 8 (7.4) | 0.032 | 16 (13.1) | 3 (13.6) | 13 (13.0) | 1.000 |
| Thrombocytopenia | – | – | – | – | 11 (8.6) | 2 (10.0) | 9 (8.3) | 0.682 | 54 (44.3) | 11 (50.0) | 43 (43.0) | 0.638 |
| Aplastic anemia | – | – | – | – | 3 (2.3) | 1 (5.0) | 2 (1.9) | 0.402 | 7 (5.7) | 3 (13.6) | 4 (4.0) | 0.110 |
Data are n (%)
Allo-HSCT allogeneic hematopoietic stem cell transplantation, BM bone marrow, CMV cytomegalovirus, SOT solid organ transplantation
aDiagnoses generally present in renal SOT patients not shown for respective patient group
bDiagnoses generally present in HSCT patients not shown for respective patient group